Ticker Sage

Company file · MEDP

Medpace

Metabolic was Medpace's fastest-growing product or service in FY2025, up 62.8%

Revenue rose 20.0% to $2.5B in FY2025, from $2.1B in FY2024. Net income rose 11.6% to $451M. Oncology was the largest product or service, at 30% of revenue.

Key facts

Medpace (Nasdaq: MEDP) reported revenue of $2.5B for fiscal 2025, the year ended Dec 31, 2025, up 20.0% from fiscal 2024. Net income was $451M, up 11.6%. In its latest 10-Q, for the quarter ended Sep 30, 2026, revenue was $716M, up 8.5% from the same quarter a year earlier, and net income was $137M. The largest piece by product or service was Oncology, at 30% of fiscal 2025 revenue. Sources: 10-K for fiscal 2025 (filed Feb 10, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Oct 22, 2026).

Revenue$2.5BFY2025 · +20.0% vs FY2024
Net income$451MFY2025 · +11.6% vs FY2024
Operating cash flow$713MFY2025 · +17.1% vs FY2024
Cash & equivalents$705Mat Sep 30, 2026 · +41.9% vs FY2025 end
Diluted shares30MFY2025 avg · −7.8% vs FY2024
Revenue and net income, three fiscal yearsBy fiscal year, $bn
RevenueNet income
Revenue and net income by fiscal yearRevenue FY2023: $1.9B1.9Net income FY2023: $283M0.28FY2023Revenue FY2024: $2.1B2.1Net income FY2024: $404M0.40FY2024Revenue FY2025: $2.5B2.5Net income FY2025: $451M0.45FY2025Data: Ticker Sage, from SEC EDGAR · tickersage.com

Source: 10-K FY2025, filed Feb 10, 2026

Quarterly revenue: fiscal 2026 vs a year earlierFiscal Q1–Q3, $bn (each quarter from that quarter's 10-Q)
FY2025FY2026
Quarterly revenue, fiscal 2026 vs 2025FY2025 Q1: $559M0.56FY2026 Q1: $707M0.71Q1FY2025 Q2: $603M0.60FY2026 Q2: $707M0.71Q2FY2025 Q3: $660M0.66FY2026 Q3: $716M0.72Q3Data: Ticker Sage, from SEC EDGAR · tickersage.com

Source: 10-Q filed Apr 23, 2026 · 10-Q filed Jul 23, 2026 · 10-Q filed Oct 22, 2026

How it makes money

FY2025 total by categoryOncology: $748M (30%)Metabolic: $745M (29%)Other: $409M (16%)Central Nervous System: $255M (10%)Cardiology: $239M (9%)Antiviral and Anti Infective: $135M (5%)$2.5BFY2025 totalData: Ticker Sage, from SEC EDGARtickersage.com

By product or service, FY2025

  • LineAmountSharevs FY2024
  • Oncology$748M30%+14.8%
  • Metabolic$745M29%+62.8%
  • Other$409M16%−5.3%
  • Central Nervous System$255M10%+40.0%
  • Cardiology$239M9%+3.9%
  • Antiviral and Anti Infective$135M5%−13.8%

Source: 10-K FY2025, XBRL breakdown

By product or service in FY2025: Oncology (30%), Metabolic (29%), Other (16%) and Central Nervous System (10%), as shares of total revenue. Total revenue was $2.5B.

By product or service: three-year mixShare of the total each fiscal year
OncologyMetabolicOtherCentral Nervous SystemCardiologyAntiviral and Anti Infective

Source: 10-K FY2025

Learn more: Revenue vs. net income · Gross, operating and net margin

What changed last quarter

How the quarter compared with a year earlier

Comparing Q3 2026 (Jul to Sep 2026) compared with Q3 2025 (Jul to Sep 2025)

Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.

Q3 2026Q3 2025

Company

Revenue
$716M Q3 2026
$660M Q3 2025
8.5% increase
Net income
$137M Q3 2026
$111M Q3 2025
23.7% increase

Source: Medpace 10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026

By product or service

Oncology
$230M Q3 2026
$193M Q3 2025
19.4% increase
Metabolic
$209M Q3 2026
$199M Q3 2025
5.0% increase
Other
$100M Q3 2026
$106M Q3 2025
6.1% decrease
Central Nervous System
$84M Q3 2026
$66M Q3 2025
27.5% increase
Cardiology
$61M Q3 2026
$59M Q3 2025
3.3% increase
Antiviral and Anti Infective
$32M Q3 2026
$37M Q3 2025
12.9% decrease

Source: Medpace 10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026

  • Cash & equivalents $705M at Sep 30, 2026, vs $497M at FY2025 end.
  • Operating cash flow, first 9 months of fiscal 2026: $530M vs $521M a year earlier.

The bull case and the bear case

The bull case

  • Revenue rose 20.0% in FY2025 to $2.5B, from $2.1B a year earlier. 10-K, FY2025
  • Net income rose 11.6% in FY2025 to $451M, from $404M. 10-K, FY2025
  • Operating cash flow rose 17.1% in FY2025 to $713M. 10-K, FY2025
  • Diluted shares fell 7.8% in FY2025, so each share represents a larger slice of profit. 10-K, FY2025

The bear case

  • Antiviral and Anti Infective revenue fell 13.8% in FY2025 to $135M. 10-K, FY2025
  • The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A

What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.

What the company does

Medpace is in the life sciences tools & services industry, part of the health care sector. The SEC files it under Services-Commercial Physical & Biological Research.

The full description of Medpace's business is in Item 1 of its 10-K, linked below. This page shows its revenue by product or service.

Its fiscal year ends in December; the latest, FY2025, ended Dec 31, 2025.

Source: 10-K, Item 1 Business

Risks common in this industry

These are general risks for companies in the life sciences tools & services industry. They are not a summary of Medpace’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.

  1. RegulationApprovals, safety rules and government oversight shape what it can sell and how.
  2. Pricing and reimbursementPayers, insurers and governments influence what it can charge.
  3. CompetitionNew treatments, generics and rival products can take share.
  4. LitigationProduct liability and other legal claims can lead to costs.
  5. SupplyManufacturing and supplier problems can interrupt products.

Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)

Three years of key numbers

Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.

US$FY2023FY2024FY2025
Revenue$1.9B$2.1B$2.5B
Net income$283M$404M$451M
Operating cash flow$433M$609M$713M
Cash & equivalents (year end)$245M$669M$497M
Diluted shares32M32M30M
  • Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
  • Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
  • Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
  • Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
  • Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.

Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator

Explainers for this page

Guides to terms this file uses, with real numbers from filings.

About these numbers

    What we left out

    • Total debt: the company's filing data doesn't carry a consistent debt total for the years shown, so it isn't shown.

    Recent filings

    FormFiledPeriod
    10-QOct 22, 2026Sep 30, 2026
    10-QJul 23, 2026Jun 30, 2026
    10-QApr 23, 2026Mar 31, 2026
    DEF 14AApr 1, 2026May 15, 2026
    10-KFeb 10, 2026Dec 31, 2025

    What's in this filing

    The quotes below come from Item 1 (Business) of the Form 10-K Medpace filed on Feb 10, 2026, its annual report for the fiscal year ended Dec 31, 2025.

    The latest quarterly report in the table above is the Form 10-Q filed Oct 22, 2026 for the quarter ended Sep 30, 2026.

    A 10-K has audited annual financial statements and the company's own description of its business and risks; a 10-Q has unaudited quarterly statements.

    We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries.

    Source: Form 10-K, Item 1 (Business), filed Feb 10, 2026

    Our mission is to accelerate the global development of safe and effective medical therapeutics.

    Source: Form 10-K, Item 1 (Business), filed Feb 10, 2026

    Short excerpts quoted from the filing. The full document is on SEC.gov.

    Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters

    Common questions about Medpace

    How does Medpace make money?

    Medpace's revenue was $2.5B in fiscal 2025. By product or service in FY2025: Oncology (30%), Metabolic (29%), Other (16%) and Central Nervous System (10%), as shares of total revenue. Total revenue was $2.5B. Source: 10-K for fiscal 2025, filed Feb 10, 2026.

    What was Medpace's revenue in fiscal 2025?

    $2.5B of revenue for the fiscal year ended Dec 31, 2025, up 20.0% from $2.1B in fiscal 2024. Fiscal 2023 was $1.9B. Source: 10-K for fiscal 2025, filed Feb 10, 2026.

    Is Medpace profitable?

    Medpace reported net income of $451M for fiscal 2025, up 11.6% from $404M in fiscal 2024. That is a profit under US accounting rules (GAAP). In the quarter ended Sep 30, 2026, net income was $137M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2025, filed Feb 10, 2026.

    What did Medpace report in its latest quarterly filing?

    Revenue was $716M in the quarter ended Sep 30, 2026, up 8.5% from $660M a year earlier. Net income was $137M, up 23.7% from $111M. Source: 10-Q for the quarter ended Sep 30, 2026, filed Oct 22, 2026.

    What are the main risks Medpace faces?

    Medpace's own risk factors are in Item 1A of its 10-K for fiscal 2025, filed Feb 10, 2026. Risks that are common among companies in the life sciences tools & services industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.

    Where do these Medpace numbers come from?

    From Medpace's own SEC filings: the 10-K for fiscal 2025 (filed Feb 10, 2026) and the 10-Q for the quarter ended Sep 30, 2026 (filed Oct 22, 2026), read through the SEC's public XBRL data. Each number on this page links to its filing. Methodology explains how fiscal years and missing numbers are handled.

    Tracked funds that report owning Medpace

    From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.

    Disclosures

    Editor holdings in MEDP
    The editor holds no position in Medpace (MEDP). As of Nov 11, 2026.
    Trading rule
    The editor does not buy or sell MEDP from 3 days before to 3 days after this page is published or substantively updated.
    Compensation
    Nobody paid for this page. No affiliate links on this page.
    Sources
    The company's SEC filings, linked next to each number or, for charts, in the source line under them.
    Last updated
    Nov 20, 2026

    General education, the same for every reader. Not a recommendation to buy, sell or hold MEDP, and it doesn't consider your situation.

    Compare with peers

    CompanyFiscal yearRevenueRevenue growthNet income
    MedpaceMEDPFY2025$2.5B+20.0%$451M
    Thermo FisherTMOFY2025$44.6B+3.9%$6.7B
    DanaherDHRFY2025$24.6B+2.9%$3.6B
    Agilent TechnologiesAFY2025$6.9B+6.7%$1.3B
    WatersWATFY2025$3.2B+7.0%$643M

    Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.

    More company files

    New to filings? Learn has explainers built on real filings and Tools has calculators. Methodology & Disclosures covers where every number comes from.